These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 6295787)

  • 21. Platelet desensitization induced by arachidonic acid is not due to cyclo-oxygenase inactivation and involves the endoperoxide receptor.
    Carmo LG; Hatmi M; Rotilio D; Vargaftig BB
    Br J Pharmacol; 1985 Aug; 85(4):849-59. PubMed ID: 2994786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation.
    Stürzebecher S; Witt W
    Prostaglandins; 1988 Dec; 36(6):751-60. PubMed ID: 2469101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
    De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F
    Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
    Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G
    Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
    Dale J; Thaulow E; Myhre E; Parry J
    Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
    Darius H; Lefer AM
    Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thromboxane synthetase inhibitors differentially antagonize thromboxane receptors in vascular smooth muscle.
    Smith EF; Lefer AM; Smith JB; Nicolaou KC
    Naunyn Schmiedebergs Arch Pharmacol; 1981 Dec; 318(2):130-4. PubMed ID: 6276789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K; Halushka PV; Yan YT; Wong PY
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid.
    Gorman RR; Bundy GL; Peterson DC; Sun FF; Miller OV; Fitzpatrick FA
    Proc Natl Acad Sci U S A; 1977 Sep; 74(9):4007-11. PubMed ID: 269449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats.
    Mallarkey G; Smith GM
    Br J Pharmacol; 1985 Feb; 84(2):425-30. PubMed ID: 3156648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
    Gresele P; Deckmyn H; Huybrechts E; Vermylen J
    Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
    Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
    Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of platelet activating factor antagonists on arachidonic acid-induced platelet aggregation and TXA2 formation.
    Heinroth-Hoffmann I; Hauser A; Mest HJ
    Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):181-2. PubMed ID: 2149184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 9,11-epoxyiminoprosta-5,13-dienoic acid is a thromboxane A2 antagonist in human platelets.
    Fitzpatrick FA; Bundy GL; Gorman RR; Honohan T
    Nature; 1978 Oct; 275(5682):764-6. PubMed ID: 703845
    [No Abstract]   [Full Text] [Related]  

  • 38. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin.
    Bertelé V; Falanga A; Roncaglioni MC; Cerletti C; de Gaetano G
    Thromb Haemost; 1982 Jun; 47(3):294. PubMed ID: 7051411
    [No Abstract]   [Full Text] [Related]  

  • 39. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
    Heylen L; De Clerck F; Somers Y; Leysen JE
    Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
    FitzGerald GA; Brash AR; Oates JA; Pedersen AK
    J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.